MedTrace Logo

Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients

NCT00919607 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2010-03-26

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the pharmacokinetics of XR quetiapine fumarate(300mg,600mg,and 800mg once-daily) in Chinese schizophrenic patients .

Conditions

Interventions

DRUG

quetiapine fumarate extended-release

200mg,oral,single dose

DRUG

quetiapine fumarate extended-release

300mg,oral,single dose

Sponsors & Collaborators

Principal Investigators

  • Tianmei Si · Peking University Institute of Mental Health

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00919607 on ClinicalTrials.gov